CLAIM #18593 · CVS Health Corp (CVS) · 2025Q3 earnings call · Oct 29, 2025 · due Dec 31, 2026
“Beginning with our Health Care Benefits business, we expect another year of meaningful margin improvement at Aetna.”
Brian O. Newman · CFO
How to check this claim
Look at: Health Care Benefits (Aetna) segment operating margin, full year 2026 vs full year 2025
It came true if: FY2026 Health Care Benefits segment operating margin higher than FY2025 reported figure
Where: CVS Health 10-K / segment reporting (Health Care Benefits segment results)
In context
“or the rest of the immunization season and potential impacts to the consumer environment. In aggregate, we now expect full year enterprise adjusted operating income to be in the range of $14.14 billion to $14.31 billion. We are also increasing our expectations for full year cash flow from operations to be in a range of $7.5 billion to $8 billion. Additionally, we now expect our full year adjusted effective tax rate to be 25.3%, an improvement of 40 basis points. You can find additional details on the components of our 2025 guidance on our Investor Relations website. Before we open the call up to Q&A, I also want to provide an update on some of the key headwinds and tailwinds for 2026. Consistent with past practice, we expect to provide formal 2026 guidance at our Investor Day in December. Beginning with our Health Care Benefits business, we expect another year of meaningful margin improvement at Aetna. This includes another year of progress in our Medicare Advantage business, supported by our disciplined approach to plan design and footprint in individual as well as repricing opportunities in our group business. We also expect a tailwind from our exit of the individual exchange business. Although our conversations with our Medicaid state partners continue to progress and this business has performed in line with our expectations this year, we are taking a cautious outlook in light of the broader pressures across the industry. In our Health Services segment, we expect improvement in our Health Care Delivery business, primarily driven by Oak Street Health. In our Caremark business, we expect modestly lower growth as we continue our work to transition our contracts towards drug level pricin”
Verify independently
SEC filings for CVS ↗ · Claim quote is verbatim from the 2025Q3 earnings call.